FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the“Company” or“Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 27, 2020 Category: Drugs & Pharmacology Source Type: news
New Drug Approved for Neuroblastoma Based on MSKCC Research New Drug Approved for Neuroblastoma Based on MSKCC Research
Naxitamab has been approved for pediatric and adult patients with relapsed/refractory neuroblastoma in the bone and bone marrow that has responded to prior therapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
(American Association for the Advancement of Science) A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2020 Category: Cancer & Oncology Source Type: news
New immunotherapy shows promise against rare childhood cancer
(University College London) A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2020 Category: International Medicine & Public Health Source Type: news
What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem.
Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints.
Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Researchers mine data and connect the dots about processes driving neuroblastoma
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists lead genome analysis to better understand one of the most common childhood solid tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 14, 2020 Category: International Medicine & Public Health Source Type: news
Promising treatment for aggressive childhood cancer
(Lund University) A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer. The study was led by researchers at Lund University in Sweden, and is published in the journal Science Translational Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news
MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma
(Science China Press) The researchers adopted the functional polymorphism research strategy to screen out the functional polymorphisms associated with neuroblastoma in Chinese population and elucidate its mechanism, providing data on children susceptible to neuroblastoma in China. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 11, 2020 Category: Biology Source Type: news
FDA grants rare disease designation to Clarity agent
Radiopharmaceutical firm Clarity Pharmaceuticals announced that the U.S. Food...Read more on AuntMinnie.comRelated Reading:
Clarity's breast imaging agent enters clinical trial
Clarity begins trial for pediatric neuroblastoma therapy
Clarity, ImaginAb team to develop theranostic agents
NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2020 Category: Radiology Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news
Clarity's breast imaging agent enters clinical trial
Radiopharmaceutical firm Clarity Pharmaceuticals said that its copper-64 SAR-Bombesin...Read more on AuntMinnie.comRelated Reading:
Clarity begins trial for pediatric neuroblastoma therapy
Clarity, ImaginAb team to develop theranostic agents
NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 29, 2020 Category: Radiology Source Type: news
Clarity begins trial for pediatric neuroblastoma therapy
Radiopharmaceutical firm Clarity Pharmaceuticals has begun recruitment for...Read more on AuntMinnie.comRelated Reading:
Clarity, ImaginAb team to develop theranostic agents
NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 23, 2020 Category: Radiology Source Type: news
Could the willow help us fight cancer?
An ingredient in its bark led to aspirin, now researchers are looking into the properties of another compound in the treeWillow trees are a pharmaceutical treasure trove. The ancient Egyptians used its bark for relieving pain, inflammation and fevers, and science has since shown these medical powers came from an ingredient called salicin, named aftersalix, the Latin name for the tree. That discovery eventually led to the manufacture of aspirin, one of the most widely used medicines in the world.Recently another potential drug has been found in willow, one with anti-cancer powers. Scientists atRothamsted Research in Hertfor...
Source: Guardian Unlimited Science - July 14, 2020 Category: Science Authors: Paul Simons Tags: Science Trees and forests Environment UK news Cancer research Medical research Source Type: news
